Table 3.

Differential CDH13 methylation, odds ratio between adenocarcinoma, squamous cell carcinoma and their counterparts from TCGA dataset

Type	CpG site	Position	McaM	McoM	∆β	P-value
LUAD	cg08747377	chr16:82660670	0.32	0.1	0.22	1.95×10-5
	cg05374412	chr16:82660727	0.21	0.03	0.18	2.27×10-5
	cg00806490	chr16:82660873	0.28	0.13	0.15	1.05×10-4
	cg08856946	chr16:82661421	0.19	0.04	0.15	2.27×10-5
	cg09189772	chr16:82661638	0.29	0.16	0.13	8.32×10-4
	cg19369556	chr16:82661725	0.26	0.22	0.04	2.92×10-1
LUSC	cg08747377	chr16:82660670	0.13	0.08	0.05	1.50×10-2
	cg05374412	chr16:82660727	0.07	0.02	0.05	9.00×10-3
	cg00806490	chr16:82660873	0.15	0.11	0.04	6.00×10-3
	cg08856946	chr16:82661421	0.05	0.03	0.02	3.00×10-2
	cg09189772	chr16:82661638	0.16	0.14	0.02	7.61×10-1
	cg19369556	chr16:82661725	0.14	0.18	0.04	2.26×10-5

McaM and McoM represent the mean of case methylation (Beta) and mean of control methylation (Beta). Methylation levels are calculated with formula: Beta = (M/M + U).

LUAD is short for lung adenocarcinoma, and LUSC is short for lung squamous cell carcinoma

Position represents the chromosome position of each CpG site according to GRCh37/hg19.

P-values are calculated from Wilcoxon signed-rank test after false discovery rate (FDR adjustment).